13F Holdings
中文EN

RNAC Cartesian Therapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1453687 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-6.0%
TTM net income YoY-165.7%
TTM EPS YoY-259.4%
Revenue 3-yr CAGR-69.0%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-15,540.9%
Net margin-12,435.2%
FCF margin-8,770.0%
EBITDA margin-15,267.7%

Returns

ROE—
ROA-38.2%
ROIC (approx.)—
Asset turnover0.00x

Leverage & solvency

Liabilities / assets144.3%
Debt / equity—
Current ratio8.38x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.70x
Accruals ratio-11.6%
Payout ratio—
Capex / revenue120.2%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$2.80M$38.91M$26.00M$110.78M$85.08M
R&D expense$58.03M$45.10M$71.26M$72.38M$68.74M
SG&A expense$31.47M$30.13M$40.45M$23.86M$20.94M
Operating income-$143.41M-$43.90M-$86.42M$14.54M-$4.60M
Interest expense—$0$2.83M$3.03M$2.84M
Pretax income-$139.50M-$77.14M-$238.71M$34.77M-$9.72M
Income tax-$9.19M$287,000-$19.00M-$609,000$15.97M
Net income-$130.30M-$77.42M-$219.71M$35.38M-$25.69M
EBITDA-$141.00M-$42.70M-$85.72M$15.24M-$4.00M
EPS (basic)-5.02-4.48-49.760.24-0.22
EPS (diluted)-5.02-4.49-49.760.10-0.22
Weighted avg. shares (diluted)25.97M17.36M5.17M145.87M114.33M
Balance sheet
Cash & equivalents$125.14M$214.28M$78.29M$108.04M$114.06M
Short-term investments——$0$28.16M$14.00M
Receivables$1.11M$872,000$5.87M$6.60M$9.91M
Current assets$129.28M$216.63M$90.73M$148.14M$144.44M
PP&E, net$12.19M$9.91M$2.11M$2.79M$2.14M
Goodwill$48.16M$48.16M$48.16M$0—
Total assets$296.41M$435.02M$305.05M$165.89M$159.88M
Current liabilities$14.94M$22.98M$68.21M$25.08M$72.25M
Long-term debt$0————
Total debt$0————
Total liabilities$422.65M$441.82M$444.68M$72.06M$137.36M
Shareholders' equity-$126.24M-$6.80M-$440.18M$93.83M$22.52M
Net debt-$125.14M————
Shares outstanding26.01M25.77M5.40M153.04M123.62M
Cash flow statement
Operating cash flow-$73.94M-$23.67M-$51.16M-$31.63M-$60.38M
Capital expenditure$5.45M$9.09M$206,000$1.20M$1.08M
Free cash flow-$79.39M-$32.77M-$51.37M-$32.83M-$61.47M
Investing cash flow-$5.45M-$8.74M$34.61M-$15.00M-$17.14M
Financing cash flow-$8.05M$168.43M-$13.14M$39.22M$52.90M
Depreciation & amortization$2.40M$1.20M$700,000$700,000$600,000
Stock-based compensation$10.52M$6.58M$22.52M$11.19M$7.72M

Free plan shows the latest 5 periods; Pro shows all 12 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.